DOES BENFOTIAMINE SUPPLEMENTATION REDUCE SERUM LEVELS OF ADVANCED GLYCATION END PRODUCTS AND BIOCHEMICAL MARKERS OF VASCULAR DYSFUNCTION IN TYPE 1 DIABETES?

Aker University Hospital0 个研究点开始时间: 2004年6月25日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•Genders Eligible for Study: Both
•Age 18 to 60 years, inclusive.
•Type 1 diabetes mellitus for at least 5 years as defined by the following:
•a. Insulin dependence
•b. C-peptide < 160 nmol/l and/or anti-GAD positive.
•In addition, microalbuminuria (urinary albumin excretion > 15 ug/min in two out of three overnight urine samples)
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•Symptomatic gastroparesis.
•Urine albumin > 200 ug/min in timed overnight urine collection. Diabetic nephropathy with a creatinine clearance less than 60 cc/min.
•Evidence of chronic infection.
•History of any malignancy.
•Any chronic medical condition that unduly increase risk for the potential enrollee as judged by study investigators.
•Pregnancy, breastfeeding or planned pregnancy within two years.

发起方

Aker University Hospital